Medicare Enrolled
Dr. Amir Salam, M.D.
Medical Oncology · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Salam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Salam?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Salam
Dr. Amir Salam is a medical oncology specialist in Houston, TX, with 16 years of NPI registration. Based on federal Medicare data, Dr. Salam performed 41,407 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Salam received a total of $13,890 from 77 pharmaceutical and/or device companies across 672 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Salam is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years of NPI registration
▲ Top 22% volume in TX
$13,890 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗41,407
Medicare services
Top 22% in TX for medical oncology
Not available
Unique patients (not deduplicated)
$2
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
39,270 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
485 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 350 | $1 | $4 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
290 | $8 | $24 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
214 | $94 | $395 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
128 | $64 | $279 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
122 | $8 | $9 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
91 | $138 | $556 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
83 | $104 | $419 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
82 | $51 | $206 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
77 | $11 | $54 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
66 | $22 | $92 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
51 | $117 | $513 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
43 | $12 | $49 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
22 | $60 | $353 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
17 | $68 | $285 |
| New patient office visit, complex (60-74 min) | 16 | $175 | $683 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
95.4% high complexity
2.3% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,890
Total received (2018-2024)
Avg $1,984/year across 7 years
Top 34% in TX for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
672
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,462
2023
$2,974
2022
$3,183
2021
$2,380
2020
$1,056
2019
$1,053
2018
$1,782
Payments by company (2024)
E.R. Squibb & Sons, L.L.C.
$196
SpringWorks Therapeutics, Inc.
$152
AstraZeneca Pharmaceuticals LP
$145
Novartis Pharmaceuticals Corporation
$127
Merck Sharp & Dohme LLC
$109
Celgene Corporation
$100
GlaxoSmithKline, LLC.
$89
Gilead Sciences, Inc.
$80
PFIZER INC.
$76
Janssen Biotech, Inc.
$72
Exelixis Inc.
$49
Tempus AI, Inc
$46
Deciphera Pharmaceuticals Inc.
$35
SOBI, INC
$29
Boston Scientific Corporation
$27
Secura Bio, Inc.
$24
Astellas Pharma US Inc
$22
Esperion Therapeutics, Inc.
$21
Lilly USA, LLC
$20
TAIHO ONCOLOGY, INC.
$18
Mirati Therapeutics, Inc.
$17
Sirtex Medical Inc
$9
Top 3 companies account for 33.7% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$1,129
AstraZeneca Pharmaceuticals LP
$821
Novartis Pharmaceuticals Corporation
$767
Janssen Biotech, Inc.
$684
PFIZER INC.
$660
Celgene Corporation
$595
GlaxoSmithKline, LLC.
$553
Merck Sharp & Dohme Corporation
$526
Merck Sharp & Dohme LLC
$485
Amgen Inc.
$481
Pharmacyclics LLC, An AbbVie Company
$419
GENZYME CORPORATION
$376
Gilead Sciences, Inc.
$342
Boehringer Ingelheim Pharmaceuticals, Inc.
$342
Exelixis Inc.
$318
Seagen Inc.
$306
Incyte Corporation
$284
Lilly USA, LLC
$268
Rigel Pharmaceuticals, Inc.
$256
Daiichi Sankyo Inc.
$254
Sirtex Medical Inc
$202
Bayer HealthCare Pharmaceuticals Inc.
$200
Takeda Pharmaceuticals U.S.A., Inc.
$197
Genentech USA, Inc.
$173
Myovant Sciences Inc.
$164
Taiho Oncology, Inc.
$154
SpringWorks Therapeutics, Inc.
$152
Puma Biotechnology, Inc.
$150
AVEO Pharmaceuticals, Inc.
$143
CTI BioPharma Corp.
$127
BeiGene USA, Inc.
$126
ARRAY BIOPHARMA INC
$124
Astellas Pharma US Inc
$123
Janssen Pharmaceuticals, Inc
$117
PUMA BIOTECHNOLOGY, INC.
$114
Eisai Inc.
$112
MorphoSys, US Inc.
$95
AbbVie Inc.
$93
Deciphera Pharmaceuticals Inc.
$91
EISAI INC.
$90
EMD Serono, Inc.
$89
Foundation Medicine, Inc.
$78
Pharmacyclics LLC, an AbbVie Company
$76
Ipsen Biopharmaceuticals, Inc
$69
Alexion Pharmaceuticals, Inc.
$58
TerSera Therapeutics LLC
$57
TESARO, Inc.
$53
Regeneron Healthcare Solutions, Inc.
$51
Tempus AI, Inc
$46
Bayer Healthcare Pharmaceuticals Inc.
$46
ABBVIE INC.
$44
Acceleron Pharma, Inc.
$42
AMAG Pharmaceuticals, Inc.
$40
Sobi, Inc
$37
Verastem, Inc.
$35
Mirati Therapeutics, Inc.
$31
Stemline Therapeutics Inc.
$29
Dova Pharmaceuticals
$29
Blueprint Medicines Corporation
$29
SOBI, INC
$29
Kite Pharma, Inc.
$27
Boston Scientific Corporation
$27
Secura Bio, Inc.
$24
Agios Pharmaceuticals, Inc.
$23
Sumitomo Pharma America, Inc.
$22
Esperion Therapeutics, Inc.
$21
Lexicon Pharmaceuticals, Inc.
$21
EUSA Pharma (US) LLC
$18
Novo Nordisk Inc
$18
TAIHO ONCOLOGY, INC.
$18
Karyopharm Therapeutics Inc.
$15
Teva Pharmaceuticals USA, Inc.
$14
Servier Pharmaceuticals LLC
$14
United Therapeutics Corporation
$13
Seattle Genetics, Inc.
$12
Bioventus LLC
$12
IBSA Pharma Inc.
$11
Top 3 companies account for 19.6% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · ALUNBRIG · AYVAKIT · Aliqopa · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · Durolane · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Enhertu · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INQOVI · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NEXLETOL · NINLARO · NONE · Nexavar · Nplate · Nubeqa · OFEV · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PROMACTA · Pomalyst · Prolia · QINLOCK · REBLOZYL · RETACRIT · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · Sylvant · TAGRISSO · TALVEY · TASIGNA · TIBSOVO · TUKYSA · Tavalisse · Tazverik · Tecentriq · TheraSphere Y90 Glass Microspheres 10 GBq · Tirosint · Tresiba · Trodelvy · Turalio · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · Vectibix · Venclexta · Vonjo · XALKORI · XARELTO · XPOVIO · XT CDX · XTANDI · Xermelo · Xospata · Xtandi · Yescarta · ZEJULA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
168
County median income
$73,104
Nearest hospital to ZIP centroid (approximate)
HOUSTON METHODIST CLEAR LAKE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Salam is a mixed practice specialist, with above-average Medicare volume (top 22% in TX), with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Salam experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Salam performed 39,270 iron infusion (feraheme) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Salam receive payments from pharmaceutical companies?
Yes. Dr. Salam received a total of $13,890 from 77 companies across 672 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Salam's costs compare to other medical oncologists in Houston?
Dr. Salam's average Medicare payment per service is $2. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Salam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Houston
Browse medical oncologists in Houston ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology